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ABSTRACT
Objective To assess the accuracy of Global Registry of
Acute Coronary Events (GRACE) scores in predicting
mortality at 6 months for people with chronic obstructive
pulmonary disease (COPD) and to investigate how it
might be improved.
Methods Data were obtained on 481 849 patients
with acute coronary syndrome admitted to UK hospitals
between January 2003 and June 2013 from the
Myocardial Ischaemia National Audit Project (MINAP)
database. We compared risk of death between patients
with COPD and those without COPD at 6 months,
adjusting for predicted risk of death. We then assessed
whether several modiﬁcations improved the accuracy of
the GRACE score for people with COPD.
Results The risk of death after adjusting for GRACE
score predicted that risk of death was higher for patients
with COPD than that for other patients (RR 1.29, 95% CI
1.28 to 1.33). Adding smoking into the GRACE score
model did not improve accuracy for patients with COPD.
Either adding COPD into the model (relative risk (RR)
1.00, 0.94 to 1.02) or multiplying the GRACE score by 1.3
resulted in better performance (RR 0.99, 0.96 to 1.01).
Conclusions GRACE scores underestimate risk of death
for people with COPD. A more accurate prediction of risk
of death can be obtained by adding COPD into the GRACE
score equation, or by multiplying the GRACE score
predicted risk of death by 1.3 for people with COPD. This
means that one third of patients with COPD currently
classiﬁed as low risk should be classiﬁed as moderate risk,
and could be considered for more aggressive early
treatment after non-ST-segment elevation myocardial
infarction or unstable angina.
INTRODUCTION
Accurate prediction of risk of death after acute cor-
onary syndromes (ACS) is important for prognosti-
cation and decision making about treatment, as
individuals at higher risk of death after ACS beneﬁt
most from early aggressive treatment.1 2 Early and
accurate assessment of future risk allows clinicians
to identify patients who might beneﬁt most from
therapies and to avoid unnecessary treatment for
those who are less likely to beneﬁt.
Global Registry of Acute Coronary Events
(GRACE) scores are used internationally to predict
the probability of death at 6 months after admission
to hospital for ACS. They have been developed and
validated in several different settings.3–7 The pre-
dicted risk of death can be used to stratify patients
into low (<3%), moderate (3%–6%) and high
(>6%) risk of death at 6 months after ACS.
Current guidelines recommend that those classiﬁed
as moderate and high risk of death using the
GRACE score should receive more aggressive early
therapy after non-ST-segment elevation myocardial
infarction (non-STEMI) or unstable angina.8 9
People with chronic obstructive pulmonary
disease (COPD) have a higher risk of myocardial
infarction (MI) than those without COPD, and car-
diovascular disease is an important cause of death
in people with COPD. In addition, COPD is very
common in people with MI, with prevalence
ranging from 10% to 17%.10 11 Several studies
have also found an increased risk of death after MI
in people with COPD compared with those
without COPD.10 12 13 Previous work14 has shown
that, after adjusting for confounders, even though
people with COPD have a higher mortality at 6
months after discharge than non-COPD patients,
they are less likely to receive angiography in hos-
pital after a non-STEMI, or to receive secondary
prevention drugs after any MI. One of the reasons
for this may be that GRACE scores may not predict
risk of death in patients with COPD as well as they
do in patients without COPD.
Using data from the UK Myocardial Ischaemia
National Audit Project (MINAP) registry, we inves-
tigated whether GRACE scores performed as well
in people with COPD as they do in people without
COPD, and how they might be improved for
people with COPD.
METHODS
Data source
MINAP is a UK registry of all admissions for ACS
to hospitals in England and Wales. The following
variables were collected which are needed for the
equation for 6-month mortality (post admission):
age, heart rate, systolic blood pressure, creatinine,
heart failure, cardiac arrest at admission,
ST-segment deviation and elevated cardiac
enzymes.15 Vital status is available through linkage
with the Ofﬁce of National Statistics (ONS) mortal-
ity data.
We included all patients with a diagnosis of
STEMI from January 2003 to June 2013, or
non-STEMI or unstable angina from January 2004
to December 2012. Diagnosis of STEMI,
non-STEMI and unstable angina were based on
physician diagnosis and records of ECG and
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cardiac biomarker ﬁndings. Records were excluded if they did
not have a patient unique identiﬁer; if patients had missing
values for presence of obstructive airway disease or smoking
history; or if ONS mortality data were missing.
We identiﬁed COPD in MINAP using a strategy previously
validated in MINAP data linked with primary care.14 Brieﬂy, we
used the obstructive airway disease indicator and a smoking
history (ex-smoker or current smoker) to identify COPD, and
this identiﬁed COPD with a misclassiﬁcation rate of <10%.
Statistical methods
GRACE scores
GRACE scores and predicted risks of death at 6 months were
constructed using published nomograms for the Fox model.16
Values available from nomograms were used to construct algo-
rithms to score patients and to convert these to predicted risk
death. As Killip class is not recorded in MINAP, we used a previ-
ously validated17 method to score patients based on Killip class
of heart failure by using in-hospital prescription of diuretics as a
proxy.
We estimated the observed and GRACE score predicted risks
of death at 6 months and compared these between people with
and without COPD. We estimated the Mantel–Haenszel risk
ratio averaged over the GRACE score deciles to estimate the
average relative risk for death at 6 months after admission for
patients with COPD with the same GRACE score as non-COPD
patients. If GRACE scores work equally well in patients with
COPD and patients without COPD, then the risk ratio would
be 1. A risk ratio of <1 would suggest that GRACE scores over-
estimate the risks of death in patients with COPD after admis-
sion; a risk ratio of >1 would suggest that GRACE scores
underestimate the risks of death in patients with COPD. We also
compared the risk of death for people with diabetes with those
who do not have diabetes, adjusted for GRACE score predicted
risk of death.
We then investigated the observed risk of death between
patients with COPD and without COPD within GRACE score
predicted levels of risk (0%–3% low, 3%–6% moderate and
>6% high).
We explored the extent of and possible reasons for missing-
ness of GRACE score variables and performed a multiple imput-
ation analysis (see details in online supplementary material).
Model modiﬁcations
We investigated several strategies for improving GRACE scores
for people with COPD. We prespeciﬁed three potential modiﬁ-
cations to the GRACE models which might improve their accur-
acy for patients with COPD: (1) adding COPD into the models
as a risk factor, (2) adding smoking history into the models as a
risk factor and (3) multiplying the predicted risk of death for
patients with COPD by the RR for risk of death for patients
with COPD compared with non-COPD patients after adjusting
for GRACE score predicted risk of death.
For the approaches which involved adding new variables to
the models (smoking and COPD), we had to respecify the
GRACE models. We did this by building logistic regression
models which included all of the GRACE variables (with or
without smoking or COPD) with death at 6 months as the
outcome and used these to predict risk of death. As an internal
validation procedure, we also bootstrapped the logistic regres-
sion models with 100 reps each, and compared the parameter
estimates with those from the main analysis.
To assess which models performed best, we calculated the
Mantel–Haenszel risk ratios to compare the risk of death at
6 months between patients with COPD and without COPD
adjusting for predicted risk of death for the model in question.
We also calculated C-statistics and Hosmer–Lemeshow goodness
of ﬁt tests. Strategies involving multiplication of risk for patients
with COPD using the existing GRACE model were compared
with the existing GRACE model. To make a fair comparison,
models which involved adding other variables (smoking or
COPD) were compared with our models which included all of
the GRACE variables. To assess how well each model stratiﬁed
risk, we also plotted the proportion of all deaths by deciles of
predicted risk of death at 6 months for the normal GRACE
model and for modiﬁcations. We calculated how many people
would be reclassiﬁed in terms of risk level (low, moderate or
high) for each modiﬁcation, we also performed this analysis
stratiﬁed by type of ACS. Finally, we also calculated the continu-
ous net reclassiﬁcation improvement (NRI) statistic18 for adding
COPD to the GRACE score model.
Ethics
This study was approved by London School of Hygiene and
Tropical Medicine (LSHTM) Observational Ethics Committee
(6468) and the MINAP academic group (13-MNP-07).
RESULTS
Patient characteristics
In total, 481 489 patients with ACS were included, of whom
58 739 (12.2%) had COPD (ﬁgure 1). Characteristics of
patients with COPD and without COPD are shown in table 1.
In terms of mortality, patients with COPD were more likely to
have died by 6 months after admission compared with those
without COPD (17.7% compared with 11.6%). Patients with
COPD, on average also had higher GRACE score predicted risk
of death than those without COPD (14.0% (SD, 12.7) com-
pared with 11.7% (SD, 12.3)).
GRACE score performance
The Mantel–Haenszel pooled risk ratio comparing risks of
death for patients with COPD with those without COPD after
adjusting for GRACE score predicted risk of death was 1.30
(95% CI 1.27 to 1.33). Observed and predicted mortality for
patients with COPD and without COPD, split by deciles of
GRACE score predicted risk of death, is presented in table 2.
These results stratiﬁed by year of admission are presented in the
online supplementary table S1. People with diabetes also had a
higher risk of death than those without diabetes with the same
GRACE score predicted risk of death; however, this was lower
than for people with COPD (RR 1.14, 95% CI 1.12 to 1.16).
Model modiﬁcations
Findings from model modiﬁcations are displayed in table 3.
Compared with the MINAP-derived GRACE score model using
the original variables, the model including COPD as a risk
factor resulted in better predictions for patients with COPD.
Including smoking history as a risk factor in the model did not
result in better predictions for patients with COPD.
Bootstrapped results did not differ from the main analysis.
Multiplying the GRACE score predicted risk of death by the RR
for risk of death for patients with COPD adjusted for GRACE
score predicted risk of death (1.3) resulted in a very close
approximation to adding COPD into the model as a risk factor.
C-statistics were improved for the model which multiplied the
risk of death for patients with COPD by 1.3 and the model
which included COPD as a risk factor. Adding smoking to the
GRACE score model did not signiﬁcantly change the C-statistic.
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Hosmer–Lemeshow statistics showed that all models tested had
adequate calibration.
The proportions of all deaths in patients with COPD in
deciles of predicted risk for the normal GRACE model, the
GRACE model multiplied by 1.3 and the MINAP-derived model
including COPD are displayed in ﬁgure 2. The plot shows a
steeper increase in the proportion of deaths in each decile for
the GRACE model multiplied by 1.3, and the MINAP-derived
model including COPD compared with the normal GRACE
model, indicating better stratiﬁcation for these two modiﬁca-
tions. Observed mortality within GRACE score predicted risk
groups for the normal GRACE model and for the modiﬁcations
for patients with COPD and without COPD is presented in
table 4.
The ﬁndings for reclassiﬁcation of risk levels after different
model modiﬁcations are displayed in table 5. Compared with the
normal GRACE score model, when patients with COPD were
stratiﬁed into risk groups based on the multiplying the GRACE
score predicted risk of death by 1.3, 33.9% of those classiﬁed as
low risk (<3%) were reclassiﬁed as moderate risk (3%–6%), and
64.3% of those who were classiﬁed as moderate risk were reclas-
siﬁed as high risk (>6%). When stratiﬁed by type of ACS, the
results were similar to the main analysis, with the exception of
change in risk group after an STEMI in the MINAP-derived
model including COPD (see online supplementary tables S2–S4).
The NRI for adding COPD to the GRACE score model was
0.133 (p<0.001) indicating an improvement in classiﬁcation of
subjects when COPD is added to the model.
The ﬁndings from the multiple imputation analysis were
similar to those from the main analysis, and are presented in the
online supplementary table S5.
DISCUSSION
We found that GRACE scores for predicting risk of death at
6 months after ACS do not perform as well for people with
COPD compared with those who do not have COPD. On
average, patients with COPD had a 30% higher risk of death
than non-COPD patients with the same GRACE score. To
improve GRACE scores for patients with COPD, one option
would be to respecify the GRACE model including COPD as a
risk factor. Alternatively, multiplying GRACE score predicted
risk of death by 1.3 for patients with COPD provides a very
close approximation.
We found that, conditional on GRACE score predicted risk of
death, patients with COPD had a higher risk of death than
non-COPD patients, indicating that these scores underestimate
the risks of death in those with COPD. One might argue that
this might be true for any comorbidity; however, when we also
estimated the relative risk of death comparing patients with dia-
betes with those without diabetes adjusted for GRACE score
predicted risk of death, although we found an increased risk,
this was much lower than for COPD. Although the relative risk
Figure 1 Flow of participants through the study. ACS, acute coronary syndromes; COPD, chronic obstructive pulmonary disease; MINAP,
Myocardial Ischaemia National Audit Project; non-STEMI, non-ST-elevation myocardial infarction; OAD, obstructive airway disease; ONS, Ofﬁce of
National Statistics.
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of death for COPD might seem modest, this may have a large
impact on patient treatment. Indeed, our results suggest that a
large portion of patients with COPD would have been reclassi-
ﬁed upwards in terms of level of risk if either of our suggested
modiﬁcations (multiplying the risk for patients with COPD by
1.3 and adding COPD to the model) to the GRACE score had
been used. We found that GRACE score predicted risk was
closer to observed risk in those with COPD. The explanation
for this is likely to be that for COPD and non-COPD patients
with the same predicted risk of death, patients with COPD have
always been at higher risk and observed mortality for all patients
has fallen since GRACE scores were created such that they now
by chance align well for those with COPD, rather than the
GRACE score performing better estimated risk of death for
those with COPD. This is consistent with our ﬁndings when we
tabulated predicted and observed risk stratiﬁed by admission
year. Although the GRACE score is the most accurate and
widely used score for predicting risk of death after admission
for ACS, others are in use. Clinicians should be aware that
scores which use similar parameters are likely to underestimate
risk of death for patients with COPD to a similar degree.
Our ﬁndings are an important contribution to discussion
around the risk-treatment paradox. The paradox is that
although people who are at highest risk of death after ACS are
most likely to beneﬁt from early aggressive therapy, they are the
least likely to receive it.19 This may go some way in explaining
why patients with COPD receive less in-hospital treatment after
MI, such as in-hospital angiography after non-STEMI. Using
risk scores and recommendations based on these to guide treat-
ment decisions is one way to resolve this paradox. However,
these risk scores must be able to predict risk of death well, they
must be able to do this around levels of risk important for deci-
sion making, and they must do this for those at high risk of
death.
Table 1 Characteristics of patients included in the analysis
Characteristic Non-COPD COPD
Age group (n=481 489)
<55 79 603 (18.8%) 6575 (11.2%)
55–64 92 446 (21.8%) 10 858 (18.5%)
65–74 101 654 (24.0%) 17 402 (29.6%)
75–84 100 660 (23.8%) 18 011 (30.7%)
≥85 48 747 (11.5%) 5893 (10.0%)
Sex (n=481 489)
Male 285 502 (67.5%) 37 135 (63.2%)
Female 137 608 (32.5%) 21 604 (36.8%)
Diagnosis (n=481 489)
STEMI 137 724 (32.6%) 14 984 (25.5%)
Non-STEMI 183 447 (43.4%) 29 198 (49.7%)
Unstable angina 101 393 (24.1%) 3136 (24.8%)
Previous MI (n=478 530) 79 733 (18.9%) 14 485 (25.1%)
Previous angina (n=477 494) 107 991 (25.7%) 19 962 (34.7%)
Previously treated hyperlipidaemia
(n=467 096)
135 236 (32.9%) 18 573 (33.2%)
Previously treated hypertension
(n=477 515)
201 174 (47.9%) 28 256 (49.0%)
Peripheral vascular disease (n=473 652) 17 216 (4.1%) 4182 (7.4%)
Cerebrovascular disease (n=476 863) 31 563 (7.5%) 5858 (10.3%)
Chronic renal failure (n=476 351) 17 368 (4.1%) 3697 (6.5%)
Chronic heart failure (n=476 324) 18 216 (4.3%) 4955 (8.7%)
Previous percutaneous coronary
intervention (n=472 614)
29 077 (7.0%) 4256 (7.5%)
Previous coronary artery bypass graft
(n=473 891)
22 567 (5.4%) 3320 (5.8%)
Smoking history (n=481 849)
Never smoker 142 254 (33.6%) 0 (0%)
Ex-smoker 151 560 (35.8%) 35 103 (59.8%)
Current smoker 129 296 (30.6%) 23 636 (40.2%)
Raised cardiac markers* (n=481 849) 365 730 (91.8%) 51 206 (92.2%)
ST-segment deviation* (n=413 253) 221 205 (60.7%) 27 165 (55.3%)
Use of diuretic in hospital* (n=481 849) 93 116 (22.0%) 19 069 (32.5%)
Mean heart rate* (n=433 721) 80.2±21.9 87.2±23.7
Mean systolic blood pressure*
(n=432 854)
139.9±28.6 138.2±29
Mean serum creatinine* (n=287 893) 101±56.6 103.4±58.3
*Mean±SD.
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; non-STEMI,
non-ST-segment elevation myocardial infarction.
Table 2 Predicted and observed mortality using the normal
GRACE model
GRACE
predicted risk
decile
Average
predicted
mortality (%)
Observed
mortality—
non-COPD (%)
Observed
mortality—
COPD (%)
1 1.3 0.6 0.8
2 2.5 1.3 2.4
3 4.0 2.4 4.6
4 5.0 3.2 6.4
5 6.5 4.5 7.4
6 8.9 7.1 12.2
7 12.4 10.7 17.1
8 17.2 16.7 21.9
9 26.6 27.2 32.1
10 48.4 44.0 47.9
COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute
Coronary Events.
Table 3 Predictive ability of modifications to the GRACE score in patients with COPD
Method for obtaining predicted risk of death
M-H pooled RR (95% CI) for death at
6 months adjusted for predicted risk of death C-statistics
Hosmer–Lemeshow
p value
Normal GRACE score (comparator for 1) 1.29 (1.28 to 1.33) 0.8166 >0.999
1. Normal GRACE score—multiply risk of
death by 1.3 for patients with COPD
0.99 (0.96 to 1.01) 0.8181 (p<0.001)* >0.999
MINAP-derived GRACE score (comparator for 2–3) 1.23 (1.20 to 1.26) 0.8322 >0.999
2. MINAP-derived GRACE score+smoking 1.20 (1.17 to 1.23) 0.8323 (p=0.274)* >0.999
3. MINAP-derived GRACE score+COPD 1.00 (0.94 to 1.02) 0.8333 (p<0.001)* >0.999
*p Values compare the C-statistics for the modified models with either the normal GRACE score or the MINAP-derived GRACE score.
COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute Coronary Events; MINAP, Myocardial Ischaemia National Audit Project.
4 Rothnie KJ, et al. Heart 2016;0:1–7. doi:10.1136/heartjnl-2016-309359
Special populations
group.bmj.com on May 20, 2016 - Published by http://heart.bmj.com/Downloaded from 
A strength of our study is that it is large and representative
of the national population, including all hospital admissions
for ACS in England and Wales. A well as our complete case
analysis, we also explored reasons for missing data and con-
ducted a multiple imputation analysis. This further analysis did
not change our conclusions. We calculated the proportion of
patients with COPD who would have changed risk category as
a result of the increase in predicted risk of death. This allowed
us to demonstrate that although the relative risk of death
adjusting for GRACE score predicted risk of death may seem
modest, at the critical region of 0%–6% predicted risk of
death, this could have resulted in a change in management for
a substantial proportion of patients with COPD. One limita-
tion of our study was that we used the National Institute for
Health and Care Excellence-amended mini-GRACE score17
rather than the model including the Killip class. We used
Table 4 Observed mortality at 6 months for patients with COPD and non-COPD patients stratified by different versions of the GRACE score
predicted risk of death
Normal GRACE score
GRACE score predicted risk level Observed mortality—non-COPD (%) Observed mortality—COPD (%)
Low (<3%) 1.0 1.9
Med (3%–6%) 3.1 5.8
High (>6%) 18.4 23.3
Normal GRACE score×1.3 for patients with COPD
GRACE score predicted risk level Observed mortality—non-COPD (%) Observed mortality—COPD (%)
Low (<3%) 1.0 1.3
Med (3%–6%) 3.1 3.8
High (>6%) 18.4 21.4
MINAP-derived GRACE score
GRACE score predicted risk level Non-observed mortality—non-COPD (%) Observed mortality—COPD (%)
Low (<3%) 1.1 1.1
Med (3%–6%) 3.4 6.0
High (>6%) 20.6 25.2
MINAP-derived GRACE score and COPD
GRACE score predicted risk level Observed mortality—non-COPD (%) Observed mortality—COPD (%)
Low (<3%) 1.1 1.4
Med (3%–6%) 3.7 4
High (>6%) 21.0 23.3
COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute Coronary Events; MINAP, Myocardial Ischaemia National Audit Project.
Figure 2 Proportion of deaths occurring in patients with COPD in each decile of predicted risk for the normal GRACE model, the GRACE model
multiplied by 1.3 for patients with COPD, and the MINAP-derived model including COPD. COPD, chronic obstructive pulmonary disease; GRACE,
Global Registry of Acute Coronary Events; MINAP, Myocardial Ischaemia National Audit Project.
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prescription of diuretics in hospital as a surrogate for acute
heart failure. However, it is highly unlikely that the differences
between patients with COPD and without COPD could be
explained by this. In addition, recent work17 has shown that
this GRACE score is a very good approximation to the full
GRACE score, and the amended mini-GRACE score is being
used in practice as it is now available on the GRACE 2.0
calculator.
There are several possible reasons why GRACE score pre-
dicted risk of death is not as accurate for patients with COPD.
Our previous work showed that the relative risk of death after
MI for patients with COPD is greater after non-STEMIs than
STEMIs,14 and non-STEMIs will be scored lower than STEMIs,
all other things being equal. In addition, the effect of COPD on
risk of death after MI was greater for younger patients with
COPD, and younger people will be scored lower on average. In
the development of the GRACE score, although several clinical
characteristics, including diabetes, hypertension and hyperlipid-
aemia were tested for inclusion as risk factors, COPD was not.20
Although some of the increased risk of death may be due to dif-
ferences in treatment, others have concluded that the GRACE
score maintains its predictive ability even in groups with differ-
ent treatment.21 In addition, among a wide range of in-hospital
treatments tested, none entered the GRACE score model as pre-
dictors of death.20 Previous work has investigated the perform-
ance of the GRACE score in other high risk groups such as
people with diabetes and with chronic renal failure.22 However,
this work only assessed the C-statistics in these groups, and did
not involve assessing the GRACE score in those with COPD.
Our ﬁndings have important clinical implications for the care of
patients with COPD after admission to hospital for ACS.
Multiplying the GRACE score predicted risk of death by 1.3 for
patients with COPD would mean that 34% of people with
COPD would move from being classiﬁed as low risk to moder-
ate risk (<3% to 3%–6%). These changes have important impli-
cations as recommendations for treatment after non-STEMI and
unstable angina are based on classiﬁcation as moderate or high
predicted risk of death. This is particularly relevant as it is
known that patients with COPD are more likely to present with
a non-STEMI than non-COPD patients and that the effect of
COPD on risk of death after MI is highest in non-STEMIs, and
after adjusting for patient characteristics, they are less likely to
receive early invasive treatment after a non-STEMI compared
with non-COPD patients.14 23
CONCLUSIONS
The GRACE score predicted risk of death after ACS does not
predict risk of death for people with COPD as well as they do
for those who do not have COPD, and underestimates risk of
death for this group. When future versions of the GRACE score
model are created, those developing the scores may want to
include COPD as a risk factor for death. Clinicians should
multiply GRACE score predicted risk of death by 1.3 to obtain
a more accurate prediction. Using this rule would mean that one
third of patients with COPD previously considered to be low
risk should be considered moderate risk and would be consid-
ered for more aggressive early treatment under current guide-
lines for non-STEMI and unstable angina.
Key messages
What is already known on this subject?
Despite being at higher risk of death following admission for
acute coronary syndromes, patients with chronic obstructive
pulmonary disease (COPD) are less likely to receive investigation
and treatment than those without COPD and this difference may
explain some of the difference in mortality. It is recommended
that those at moderate (3%–6%) or high (>6%) Global Registry
of Acute Coronary Events (GRACE) score predicted risk of death
at 6 months after admission to hospital for non-ST-segment
elevation myocardial infarction or unstable angina receive earlier
aggressive investigation and treatment.
What might this study add?
This nationwide multicentre study involving 481 849 hospital
admissions demonstrates that GRACE scores underestimate risk
of death after acute coronary syndromes for those with COPD.
This study also found that multiplying the predicted risk of
death for those with COPD by 1.3 provides a better
approximation for their risk of death.
How might this impact on clinical practice?
Using a more accurate estimate of risk of death for those with
COPD after admission for acute coronary syndromes one third of
patients with COPD previously categorised as low risk would be
reclassiﬁed as moderate risk, and therefore would be eligible for
earlier, more aggressive investigation and treatment.
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Table 5 Changes in level of risk for patients with COPD after
modifications
Multiplying risk by 1.3
GRACE score predicted
risk of death
Low risk
(<3%)
Moderate risk
(3%–6%)
High risk
(≥6%)
Low risk (<3%) 4107 (66.1%) 2108 (33.9%) 0
Moderate risk (3%–6%) 0 2000 (35.7%) 3609 (64.3%)
High risk (>6%) 0 0 20 799 (100.0%)
Adding COPD into MINAP-derived GRACE model
GRACE score predicted
risk of death
Low risk
(<3%)
Moderate risk
(3%–6%)
High risk
(≥6%)
Low risk (<3%) 4635 (71.5%) 1582 (25.5%) 184 (3.0%)
Moderate risk (3%–6%) 681 (12.2%) 2792 (50.0%) 2117 (37.9%)
High risk (>6%) 15 (0.1%) 994 (4.8%) 19 527 (95.1%)
COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute
Coronary Events; MINAP, Myocardial Ischaemia National Audit Project.
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